Prednisolone but Not PTX Improves 28-Day Mortality in Patients with Alcoholic Hepatitis
Maria Vinall, Mark R. Thursz
Abstract
Maria Vinall, Mark R. Thursz
Abstract
Severe alcoholic hepatitis, has a 28-day mortality rate of about 35%. Clinical trials have shown both corticosteroids and pentoxifylline (PTX) to be of potential therapeutic benefit, however, both are controversial. This article discusses data from the Steroids or Pentoxifylline for Alcoholic Hepatitis trial [STOPAH; ISRCTN88782125].
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Severe alcoholic hepatitis, has a 28-day mortality rate of about 35%. Clinical trials have shown both corticosteroids and pentoxifylline (PTX) to be of potential therapeutic benefit, however, both are controversial. This article discusses data from the Steroids or Pentoxifylline for Alcoholic Hepatitis trial [STOPAH; ISRCTN88782125].
Key concepts: Pentoxifylline, Alcoholic hepatitis, Medicine, Prednisolone, Alcoholic liver disease, Hepatitis, Internal medicine, Gastroenterology